Objective
To compare the efficacy and safety of of pregabalin, gabapentin, carbamazepine and topiramat in migraine.
Research design and methods
In this observational study, 24 patients received pregabalin, gabapentin, carbamazepine and topiramat orally twice daily, each for 6 month with optional dose up titration (divided in four groups, each group has 6 patients). Pain diagnosis of migraine was made according to the second edition of the International Classification of Headache Disorders (ICHD-2) criteria and pain relief was measured by the patient’s global assessment of efficacy, using the Migraine Disability Assessment Questionnaire (MIDAS). Treatment goals include restoring function and improving pain control.
Results
There was a significant improvement in pain with all treatments compared with their baseline values. There were no significant differences in various other outcome measures between the groups.
Conclusions
Both carbamazepine and topiramat demonstrated similar efficacy in migraine but pregabalin, gabapentin was less effective on pain.
No conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.